Selvester score predicts implantable cardioverter defibrillator shocks in patients with non-ischemic cardiomyopathy

被引:1
|
作者
Arisoy, Fazil [1 ]
Ozcan Celebi, Ozlem [2 ]
Erbay, Ilke [2 ]
Tufekcioglu, Omac [2 ]
Aydogdu, Sinan [2 ]
Temizhan, Ahmet [2 ]
机构
[1] Kilis State Hosp, Dept Cardiol, Kilis, Turkey
[2] Univ Hlth Sci, Ankara City Hosp, Dept Cardiol, Ankara, Turkey
关键词
ICD; non ischemic cardiomyopathy; Selvester score; shock; SUDDEN CARDIAC DEATH; QRS SCORE; PRIMARY PREVENTION; THERAPY; MANAGEMENT; AMIODARONE;
D O I
10.1002/joa3.12571
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The implantable cardiac defibrillator is the cornerstone of prevention of sudden cardiac death in non-ischemic cardiomyopathy. The Selvester score, which is frequently investigated in ischemic cardiomyopathy, has not been investigated in the field of non-ischemic cardiomyopathy. Aim: The aim of this study was to evaluate the Selvester score for determining appropriate implantable cardiac defibrillator shocks in non-ischemic cardiomyopathy patients. Materials and methods: In all, 131 non-ischemic cardiomyopathy patients were included in the study. A simplified Selvester score was calculated from ECG data. Patients were divided into two groups according to whether they received ICD shock. Results: Of the patients, 28.2% received appropriate implantable cardiac defibrillator shock. The Selvester score was significantly higher in patients receiving appropriate shock when compared to patients with no implantable cardiac defibrillator shocks (8.8 +/- 4.6 vs 7.2 +/- 3.3, P = .040). The median QRS duration was significantly longer in patients receiving appropriate shock than in patients with no shocks (130.14 +/- 35.08 ms vs 120.12 +/- 20.57 ms, P = .045). We determined that the cutoff value for the Selvester score to predict ICD shocks was 6.5 with a sensitivity of 72.0% and a specificity of 83% (AUC = 0.717; %95 GA: 0.627-0.807, P < .001). Conclusion: Selvester score was higher in patients receiving appropriate shock than in patients who did not receive any implantable cardiac defibrillator shock. From this study, the Selvester score is associated with the risk of ventricular tachycardia/ventricular fibrillation in non-ischemic cardiomyopathy so that careful attention is necessary to manage the patients with high Selvester score.
引用
收藏
页码:1046 / 1051
页数:6
相关论文
共 50 条
  • [21] CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy
    Keil, Laura
    Chevalier, Celeste
    Kirchhof, Paulus
    Blankenberg, Stefan
    Lund, Gunnar
    Muellerleile, Kai
    Magnussen, Christina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (13)
  • [22] Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials
    Jorge Romero
    Rahul Chaudhary
    Jalaj Garg
    Florentino Lupercio
    Neeraj Shah
    Rahul Gupta
    Talha Nazir
    Babak Bozorgnia
    Andrea Natale
    Luigi Di Biase
    Journal of Interventional Cardiac Electrophysiology, 2017, 49 : 263 - 270
  • [23] PHANTOM SHOCKS IN PATIENTS WITH AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
    Juan, Emerson A.
    Pollack, Marc
    JOURNAL OF EMERGENCY MEDICINE, 2010, 38 (01): : 22 - 24
  • [24] Inappropriate shocks after implantable cardioverter-defibrillator for primary prevention in idiopathic cardiomyopathy: Independent determinants
    Safak, Erdal
    D'Ancona, Giuseppe
    Ince, Hueseyin
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 223 : 512 - 513
  • [25] Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients
    Smit, Marcelle D.
    Van Dessel, Pascal F. H. M.
    Rienstra, Michiel
    Nieuwland, Wybe
    Wiesfeld, Ans C. P.
    Tan, Eng S.
    Anthonio, Rutger L.
    Van Veldhuisen, Dirk J.
    Van Gelder, Isabelle C.
    EUROPACE, 2006, 8 (08): : 566 - 572
  • [26] Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis
    Briongos-Figuero, Sem
    Estevez, Alvaro
    Luisa Perez, M.
    Martinez-Ferrer, Jose B.
    Garcia, Enrique
    Vinolas, Xavier
    Arenal, Angel
    Alzueta, Javier
    Basterra, Nuria
    Rodriguez, Anibal
    Lozano, Ignacio
    Munoz-Aguilera, Roberto
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 274 : 163 - 169
  • [27] Understanding Implantable Cardioverter-Defibrillator Shocks and Mortality
    Williams, Eric S.
    Poole, Jeanne E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : 1680 - 1682
  • [28] Uncovering Phantom Shocks in Cardiac Patients with an Implantable Cardioverter Defibrillator
    Bilanovic, Ana
    Irvine, Jane
    Kovacs, Adrienne H.
    Hill, Ann
    Cameron, Doug
    Katz, Joel
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2013, 36 (06): : 673 - 683
  • [29] Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy
    Francia, Pietro
    Adduci, Carmen
    Palano, Francesca
    Semprini, Lorenzo
    Serdoz, Andrea
    Montesanti, Dalma
    Santini, Daria
    Musumeci, Beatrice
    Salvati, Adriano
    Volpe, Massimo
    Autore, Camillo
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2015, 26 (08) : 893 - 899
  • [30] Shocks after implantable cardioverter-defibrillator implantation in idiopathic cardiomyopathy patients: a myocardial biopsy study
    Erdal Safak
    Giuseppe D´Ancona
    Heinz-Peter Schultheiss
    Uwe Kühl
    Stephan Kische
    Hilmi Kaplan
    Hüseyin Ince
    Jasmin Ortak
    Heart and Vessels, 2018, 33 : 205 - 211